A case series and systematic literature review of anakinra and immunosuppression in idiopathic recurrent pericarditis

Summary Idiopathic recurrent pericarditis (IRP) impairs quality of life. Although its precise etiology is not certain, it is believed to be immunologically mediated. Its optimal treatments are unknown. Initial therapy is with non-steroidal anti-inflammatory drugs and colchicine. Steroids, which are...

Full description

Saved in:
Bibliographic Details
Published in:Journal of cardiology cases 2011-10, Vol.4 (2), p.e93-e97
Main Authors: Scott, Ian C., MBChB, MRCP, MSc, Hajela, Vijay, MBBS, FRCP, Hawkins, Philip N., PhD, FRCP, FRCPath, Lachmann, Helen J., MD, FRCP
Format: Article
Language:English
Subjects:
Cardiovascular
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Summary Idiopathic recurrent pericarditis (IRP) impairs quality of life. Although its precise etiology is not certain, it is believed to be immunologically mediated. Its optimal treatments are unknown. Initial therapy is with non-steroidal anti-inflammatory drugs and colchicine. Steroids, which are often used, however may promote recurrences. European guidelines advocate azathioprine or cyclophosphamide in refractory cases despite limited evidence. We report two adults with IRP successfully treated with the interleukin-1 antagonist, anakinra. We combine this experience with the first systematic literature review of immunosuppression in IRP. A total of 8 papers were included in the review, which alongside our patients described 18 cases. The best treatments comprised anakinra and intravenous immunoglobulin, with respective remission rates of 100% and 67%. Cyclophosphamide and azathioprine were less efficacious. The unprovoked inflammatory episodes in our patients alongside their prompt response to anakinra indicate that in some instances IRP may represent an autoinflammatory condition. We suggest that in IRP refractory to initial treatment, anakinra should be considered as a potential therapy. Clinical trials are required to confirm its benefits in IRP.
ISSN:1878-5409
1878-5409
DOI:10.1016/j.jccase.2011.07.003